January 21, 2021
Chimerix, Inc., a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, has announced the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of US$8.50 per share. All of the shares to be sold in the offering are being sold by Chimerix. The gross proceeds to Chimerix from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be US$100 million. In addition, Chimerix has granted the underwriters a 30-day option to purchase up to an additional 1,764,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 25, 2021.
Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and San Diego partner Michael Sullivan, with associates Denis Griffin, Christopher West, and Shelby Harrison.